Compare Amylx Pharmaceuticals Inc (AMLX) vs KB Financial Group, Inc. (KB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs KB Financial Group, Inc. — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while KB Financial Group, Inc. trades at $124.01 (market cap $42.55B). The key difference: KB Financial Group, Inc. is far larger — about 21.5× Amylx Pharmaceuticals Inc's market cap, and KB Financial Group, Inc. pays a 2.55% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | KB | |
|---|---|---|
Market Cap | $1.98B | $42.55B |
Sector | Health | Financials |
52-Week High | $18.70 | $123.19 |
52-Week Low | $7.64 | $77.50 |
Enterprise Value | $1.70B | — |
Dividend Yield | — | 2.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
KB Financial Group (KB) trades at $123.19, up 6.78% today, showing strong momentum with consistent earnings beats in recent quarters. The stock exhibits bullish technical signals from moving averages, though oscillators suggest caution with RSI near overbought levels. Fundamentally, revenue grew to $21.23T in 2025 with a net income margin of 27.82%, supported by diversification into non-banking segments. Analyst sentiment is mixed with a 33% buy rating, while recent news highlights dividend potential and non-banking growth.
The outlook for KB remains positive due to earnings growth and strategic diversification, but risks include reliance on interest income and macroeconomic sensitivity. Near-term resistance at $121 could limit upside, while support at $112 provides a cushion. Institutional holdings and dividend focus offer stability, yet investors should monitor interest rate impacts and competitive pressures in the banking sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →
